Cancer is characterized by a high degree of heterogeneity acquired through disease progression. Despite recent advances in cancer screening and management, limited response rates and adverse therapy-related effects have been observed in a significant proportion of cancer patients. Therefore, potential improvements in understanding current treatment approaches and innovative clinical trials are needful to improve the therapeutic efficacy and timely evaluation of patient’s response.
Mitochondria and mitochondrial homeostasis have been shown to play a critical role in the pathology of various medical conditions. Mitochondrial genes and mitochondrial epigenetics have immense potential for developing early cancer detection or cancer prognosis markers. Mitochondrial response and dynamics are the major driving factors of cell differentiation and have important therapeutic potential for various disease conditions. Mitophagy the selective elimination of damaged mitochondria, and thereby toxic reactive oxygen species from the cells generally results in the survival of cancer cells and results in residual diseases. Understanding mitochondrial plasticity will pave the way to improve the quality of cancer therapy responses and decrease therapy-assisted adverse effects.
We welcome Original Research, Reviews and Mini-Review, Methods, Case Reports, and Experimental and Clinical Research articles related to the theme of Mitochondrial dynamics in cancer stem cells. Studies focusing on metabolic plasticity and therapeutic approaches targeting mitophagy are especially welcomed.
Potential topics include but are not limited to the following:
1. Cancer stem cells in carcinogenesis and progression.
2. Mitochondrial dynamics and metabolic signatures in cancer stem cells responsible for therapy resistance.
3. Mitochondrial redox signatures in cancer recurrence and the importance of redox dynamics for host protection against carcinogenesis.
4. Pre-clinical and/or clinical targeting of mitophagy.
5. Cancer stem cells in the host immune response against cancer and/or resistance to therapy.
6. Hypoxia in the tumor microenvironment leading to immunosuppression, and tumor metastasis and progression.
7. Mitochondrial epigenetics and circulating mtDNA as diagnostic and prognostic biomarkers for cancers.
8. Metabolic plasticity in cancer stem cells and adaptations with TME leading to therapy resistance, metastasis, and recurrence.
9. Recent advances and technologies used to study real-time status of cancer stem cells and their interactions with host microenvironment.
10. Recent understandings and therapeutic approaches in cancer patients with COVID-19 disease.
Cancer is characterized by a high degree of heterogeneity acquired through disease progression. Despite recent advances in cancer screening and management, limited response rates and adverse therapy-related effects have been observed in a significant proportion of cancer patients. Therefore, potential improvements in understanding current treatment approaches and innovative clinical trials are needful to improve the therapeutic efficacy and timely evaluation of patient’s response.
Mitochondria and mitochondrial homeostasis have been shown to play a critical role in the pathology of various medical conditions. Mitochondrial genes and mitochondrial epigenetics have immense potential for developing early cancer detection or cancer prognosis markers. Mitochondrial response and dynamics are the major driving factors of cell differentiation and have important therapeutic potential for various disease conditions. Mitophagy the selective elimination of damaged mitochondria, and thereby toxic reactive oxygen species from the cells generally results in the survival of cancer cells and results in residual diseases. Understanding mitochondrial plasticity will pave the way to improve the quality of cancer therapy responses and decrease therapy-assisted adverse effects.
We welcome Original Research, Reviews and Mini-Review, Methods, Case Reports, and Experimental and Clinical Research articles related to the theme of Mitochondrial dynamics in cancer stem cells. Studies focusing on metabolic plasticity and therapeutic approaches targeting mitophagy are especially welcomed.
Potential topics include but are not limited to the following:
1. Cancer stem cells in carcinogenesis and progression.
2. Mitochondrial dynamics and metabolic signatures in cancer stem cells responsible for therapy resistance.
3. Mitochondrial redox signatures in cancer recurrence and the importance of redox dynamics for host protection against carcinogenesis.
4. Pre-clinical and/or clinical targeting of mitophagy.
5. Cancer stem cells in the host immune response against cancer and/or resistance to therapy.
6. Hypoxia in the tumor microenvironment leading to immunosuppression, and tumor metastasis and progression.
7. Mitochondrial epigenetics and circulating mtDNA as diagnostic and prognostic biomarkers for cancers.
8. Metabolic plasticity in cancer stem cells and adaptations with TME leading to therapy resistance, metastasis, and recurrence.
9. Recent advances and technologies used to study real-time status of cancer stem cells and their interactions with host microenvironment.
10. Recent understandings and therapeutic approaches in cancer patients with COVID-19 disease.
